



Abstracting & Coding Boot Camp: Cancer Case Scenarios



2015-2016 NAACCR Webinar Series



○○○○○ Q&A

- Please submit all questions concerning webinar content through the Q&A panel.
- Reminder:
- If you have participants watching this webinar at your site, please collect their names and emails.
 - We will be distributing a Q&A document in about one week. This document will fully answer questions asked during the webinar and will contain any corrections that we may discover after the webinar.

○○○○○ Fabulous prizes



○○○○○ Agenda

- Updates
- Anatomy and Medical Terminology
- Data Items/Epi Moment
- Staging
- Break
- Treatment
- Review of Take Home Quizzes

2016 & 2017 Updates

○○○○○

5

○○○○○ Stage Data Items

- For cases diagnosed 2015 and earlier all CS data items are required
- Data items going away for cases diagnosed 2016 and after.
 - CS Ext
 - CS Tumor Size
 - CS Tumor Size/Ext Eval
 - CS Lymph Nodes
 - CS Lymph Nodes Eval
 - CS Mets at DX
 - CS Mets Eval
 - CS Mets at Dx-Bone, Brain, Liver, Lung

6



○○○○○ New Stage Data Items

- Tumor Size Summary (NPCR and CoC)
- Tumor Size Clinical (SEER only)
- Tumor Size Pathologic (SEER only)
- Mets at Diagnosis - Distant Lymph Nodes
- Mets at Diagnosis – Bone
- Mets at Diagnosis – Brain
- Mets at Diagnosis – Liver
- Mets at Diagnosis – Lung
- Mets at Diagnosis – Other

7



○○○○○ Stage Data Items

- Data items we will continue to collect for cases diagnosed 2016 and forward.
 - Regional Nodes Positive and Regional Nodes Examined
 - CS Input Original and CS Input Current
 - These items are generated by your computer
 - CS Site Specific Factors (SSF)
 - For 2016 CoC requires the same SSF's as in 2015
 - For 2016 SEER and NPCR have dropped some of the their requirements
 - Lymph Vascular Invasion
 - For Penis and Testis schemas

8



○○○○○ TNM Classification Designator (c&p)

- Beginning with cases abstracted using the v16 layout, a “c” or “p” classification designator will be added to all T, N, and M values.
 - The designators indicate how the values entered into the T, N, and M data items were assigned.
 - This will make it easier to show when a clinical value is used to determine a pathologic stage or when a pathologic value is used to determine a clinical stage.

9



○○○○○ TNM Classification Designator (c&p)

- All cases diagnosed after 1/1/2016 will need to have a classification designator included in the T, N, or M values.
- CoC will require their reporting facilities to add the classification designators to the T, N, and M values to historical cases on their registry. They will also require that all cases abstracted after the v16 update include the classification indicators regardless of diagnosis year.
- State and regional registries will have to determine if they want cases diagnosed prior to 2016 to include the classification designators.
 - In the central registry database
 - Incoming records

10



○○○○○ Updates

- AJCC 8th Edition
 - Scheduled for release mid 2016
 - Effective for cases diagnosed 2017 and forward
- FORDS 2016
 - <https://www.facs.org/quality-programs/cancer/ncdb/registrymanuals/cocmanuals/fordsmanual>
- Cancer Program Standards 2016
 - <https://www.facs.org/quality-programs/cancer/coc/standards>

11



○○○○○ Updates

- Summary Stage 2017
- ICD O 3 Implementation
- Solid Tumor Coding Manual and Solid Tumor Database
 - Will replace the MP/H Manual
- Hematopoietic Database
- SEER Rx
 - The web-based version is updated in real time.
 - Stand alone version requires periodic updates (auto updates).
- NAACCR Vol II Appendix G- Recommended Abbreviations for Abstractors
 - <http://www.naacr.org/Applications/ContentReader/Default.aspx?c=17>

12



○○○○○ Revision of TNM Staged By Data Items

- The length of the TNM Path Staged By and TNM Clin Staged By data items has been expanded to 2 digits to accommodate new codes.
- The historic 1 character codes will be converted to the new codes upon upgrade to NAACCR v16-compliant software.

13



Questions?

○○○○○

14



Anatomy and Medical Terminology

○○○○○

Quiz 1

15



Questions?

○○○○○

16

Data Items : Outcomes

○○○○○

Date of First Recurrence
Type of First Recurrence
Date of Last Contact
Vital Status
Cancer Status

17

○○○○○ Data Items: Outcomes

- Date of First Recurrence
 - Measure the effectiveness of first course treatment
- Type of First Recurrence
 - Used to evaluate treatment effectiveness and as a long-term prognostic factor

18

○○○○○ Date Items: Outcomes

- **Date of Last Contact**
 - Used for patient follow-up and outcomes studies
- **Vital Status**
 - Verifies the vital status of patient as of the date entered in Date of last Contact
- **Cancer Status**
 - Records if there is clinical evidence of the patients cancer as of the Date of Last Contact

<http://cancerbulletin.facs.org/forums/forum/fords-national-cancer-data-base/fords/treatment-outcomes/cancer-status/1306-cancer-status>

19



○○○○○

And now a brief pause for...

An Epi Moment

(theme song of the moment... "I Will Survive")

20




Follow-up variables commonly used in research

- Vital Status
- Cause of death
- Date last contact
- Treatment
- Treatment dates
- Cancer status
 - NCDB only
- Recurrence
 - NCDB only




Survival Analysis

- Survival analysis is used to assess the success of cancer treatment programs and cancer control programs
- Required variables: vital status (or some other outcome like recurrence) and date of last follow-up (if not deceased or no recurrence) and cause of death
- *Survival rate*: summary variable-% of people alive after a given period of time
 - Observed, expected, relative, cause-specific
- Survival curve
- Censoring



○○○○○ Coming soon.....

- Inclusion criteria
 - Consent
 - CINA high quality data
 - SEER standard for follow-up
 - 90% of patients have current follow-up dates (or deceased)
 - 2005-2011-
 - follow-up dates Jan 1, 2012+
 - OR state & national death linkages
 - 8 of 13 Canadian Provinces
 - 63% national coverage
 - 1 no consent; 1 data quality not met
 - 3 did not meet follow-up criteria
 - 28 of 51 US states+ DC
 - 62% of US
 - 2 no consent; 3 data quality not met
 - 18 did not meet follow-up criteria



○○○○○ Outcomes research

- What treatment is effective?
 - Survival, interventions (screening and early diagnosis)
- Are standards of care followed?
- Comparative effectiveness research (CER)
- Impact of treatment delay
- Disparities in care
 - SES, insurance status or type, distance to care, regional or hospital differences,



○○○○○ Recent publications

1. Jemal A, Lin CC, DeSantic C, Sineshaw HM, Freedman RA. *Temporal trends in and factors associated with receipt of contralateral prophylactic mastectomy among US men diagnosed with breast cancer*. JAMA Surgery. 2015 Sep 2;3. Doi: 10.1001/jamasurg.2015.2657. [PubMed Abstract](#) [Full Article](#)
2. Seiber EE, Camacho F, Zeeshan MF, Kern TT, Fleming ST. *Disparities in colorectal cancer treatment delay within Appalachia—The role of for-profit hospitals*. J Rural Health, 2015. 31(4):382-91. [PubMed Abstract](#)
3. Fleming ST, Mackley HB, Camacho F, Seiber EE, Gusani NJ, Matthews SA, Liao J, Yang TC, Hwang W, Yao N. *Clinical, sociodemographic, and service provider determinants of guideline concordant colorectal cancer care for Appalachian residents*. J Rural Health;30(1):27-39. [PubMed Abstract](#) [Full Article](#)
4. Weir HK, Johnson CJ, Mariotto AB, Turner D, Wilson RJ, Nishri D, Ward KC. *Evaluation of North American Association of Central Cancer Registries' (NAACCR) data for use in population-based cancer survival studies*. J. Natl Cancer Inst Monogr. 2014;49:198-209. [PubMed Abstract](#) [Full Article](#)
5. Edwards, B.K., et al., *Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer*. Cancer, 2014. 120(9): p. 1290-314. [PubMed Abstract](#) [Full Article](#)
6. Boscoe, F.P., et al., *Geographic proximity to treatment for early stage breast cancer and likelihood of mastectomy*. Breast, 2011. 20(4): p. 324-8. [PubMed Abstract](#) [Full Article](#)

25

Questions?

○○○○○

26



Staging



Quiz 2



Break





Treatment

○○○○○

Quiz 3



Questions?

○○○○○



Take Home Quizzes

○○○○○

MP/H

Staging



Questions?

○○○○○

○○○○○ Coming Up...

- Collecting Cancer Data: Ovary
 - 4/7/16
- Collecting Cancer Data: Kidney
 - 5/5/16

○○○○○ Fabulous prizes





○○○○○ CE Certificate Quiz/Survey

- Phrase
Outcomes
- Link
 - <http://www.surveygizmo.com/s3/2617467/Boot-Camp-2016>

35



Thank You!

○○○○○

Jim Hofferkamp, CTR
Angela Martin, CTR
Recinda Sherman, PhD, CTR

jhofferkamp@naaccr.org
amartin@naaccr.org
rsherman@naaccr.org

36